Article

Youth, Young Adults Have Worse Glycemic Control Than in the Past

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.

Faisal Malik, MD, MSHS

Faisal Malik, MD, MSHS

Findings of a new analysis suggest although new technologies and therapies are available, today’s youth and young adults with diabetes in the US do not demonstrate improved glycemic control compared to their counterparts from previous years.

The findings, published as part of the American Diabetes Association’s (ADA’s) 80th Virtual Scientific Sessions, demonstrated a large percentage of current youth and young adults with diabetes did not meet current expert-recommended A1c goals, among other key findings.

“These results suggest that not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets for youth with diabetes over time,” lead study author Faisal Malik, MD, MSHS, said in a statement.

Malik and a team of investigators examined trends in glycemic control in 6492 participants with diabetes for more than 1 year from the SEARCH for Diabetes in Youth study. SEARCH began in 2000 and currently has more than 27,000 participants across racial and ethnic backgrounds from 10 different states visiting 1 of 5 study centers in the country.

The team categorized participant visit data into 3 time periods: 2002-2007, 2008-2013, and 2014-2019. Participants were also categorized into 3 groups based on the duration of their diabetes—1-4 years, 5-9 years, and >10 years—and groups based on their age group—10-14 years old, 15-19 years old, 20-24 years old, and >25 years old. Multivariable regression models were used to test differences in hemoglobin A1c over time.

The investigators found many participants did not meet current recommended A1c goals. The estimated average for the most recent group of participants with type 1 diabetes being 8.7% and 8.5% for those with type 2 diabetes.

Patients who had study visits between 2014-2019 had average A1c levels comparable to earlier SEARCH cohorts. The time period 2008-2013 also had higher levels compared to 2002-2007 (P <.01). But current participants with type 1 diabetes in the 10-14, 15-19, and. 20-24 years old age groups continue to have worse glycemic control than the 2002-2007 group. Participants >25 years old with type 2 diabetes showed a trend of worse glycemic control relative to earlier time periods.

“The increasing trends in the burden and risk of both type 1 and type 2 diabetes suggest there is a need to continue and likely expand comprehensive and sustainable surveillance efforts in youth and young adults,” study co-author Dana Dabelea, MD, PhD, said in a statement.

The findings, Dabelea said, have contributed to a better understanding of the complex and heterogeneous nature of diabetes in youth.

“Given the evidence of early complications despite current therapeutic approaches, continuing the long-term follow up of youth with diabetes is necessary to expand our understanding of its natural history, so the most appropriate approaches to primary, secondary, and tertiary prevention of diabetes and its complications can be developed and implemented,” Dabelea said.

The study reinforced the need for interventions to combine the use of diabetes technology with effective behavioral and social approaches to improve A1c levels, Malik concluded.

The study, “Trends in Glycemic Control among Youth with Diabetes: The Search for Diabetes in Youth Study,” was published as part of ADA 2020.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.